Phase 3 open-label non-inferiority RCT in 1112 adults ≥60 years: co-administering adjuvanted RSVPreF3 and PCV20 was non-inferior to giving them 1 month apart for RSV-A, RSV-B and all 20 pneumococcal serotype responses, with similar safety.
RCTn = 1,112
Leroux-Roels et al. Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial